LONE TREE, Colo., June 6, 2016 /PRNewswire/ — Zynex (OTCQB: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, neurodiagnostic equipment, cardiac and blood volume monitoring, announces today the hire of David “Skip” Mogill as Vice President of Operations. Robert Cozart that had served in this position for over 9 years retired at the end of May this year.
Mr. Mogill has more than 30 year of experience in the medical device industry with proven leadership in production, supply chain and operational process efficiency roles. Prior to joining Zynex, Mr. Mogill served as Vice President of Operations with Surgical Technologies Sector SQE and Solta Medical/SST. Previously, Mr. Mogill served in various operations management positions with Glucon Inc., Dentsply International and various other medical device manufacturing companies including Covidien between 1986 and 2006. Mr. Mogill holds a BS in Mechanical Engineering Technology from Metro State University of Denver.
Thomas Sandgaard, CEO, commented: “I am excited to have Skip Mogill on board leading our production, quality and supply chain operations. His operations and management experience in the medical device industry is a great asset as well as his experience with both large and smaller organizations. We have an exciting challenge ahead of us keeping up with the huge demand for our products after the departure of the biggest competitor in our market.”
Zynex, founded in 1996, markets and sells its own design of electrotherapy medical devices used for pain management and rehabilitation; and the company’s proprietary NeuroMove device designed to help recovery of stroke and spinal cord injury patients. Zynex is also developing a new blood volume monitor for use in hospitals and surgery centers. For additional information, please visit: Zynex.com.
Safe Harbor Statement
Certain statements in this release are “forward-looking” and as such are subject to numerous risks and uncertainties. Actual results may vary significantly from the results expressed or implied in such statements. Factors that could cause actual results to materially differ from forward-looking statements include, but are not limited to, the need to obtain additional capital or augment our liquidity in order to continue our business, the success of our compound pharmacy and international expansion efforts, our ability to engage additional sales representatives, the success of such additional sales representatives, the need to obtain FDA clearance and CE marking of new products, the acceptance of new products as well as existing products by doctors and hospitals, larger competitors with greater financial resources, the need to keep pace with technological changes, our dependence on the reimbursement from insurance companies for products sold or rented to our customers, acceptance of our products by health insurance providers, our dependence on third party manufacturers to produce our goods on time and to our specifications, implementation of our sales strategy including a strong direct sales force, the uncertain outcome of pending material litigation and other risks described in our filings with the Securities and Exchange Commission including the “Risk Factors” section of our Annual Report on Form 10-K for the year ended December 31, 2015.